Recombinant Human TDP-43/TARDBP Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human TDP-43/TARDBP Protein, CF Summary

• Details of Functionality: Typical protein concentration for in vitro use depends on the specific application.
• Source: E. coli-derived human TDP-43/TARDBP protein
• Accession #: NP_031401.1
• Protein/Peptide Type: Recombinant Enzymes

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 45 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -70 °C as supplied.
  • 3 months, -70 °C under sterile conditions after opening.
• Buffer: Supplied as a solution in HEPES, NaCl, DTT, Glycerol and Urea.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human TDP-43/TARDBP Protein, CF

• ALS10
• ALS10TAR DNA-binding protein-43
• TAR DNA binding protein
• TARDBP
• TDP43
• TDP-43
• TDP-43TAR DNA-binding protein 43

Background

TDP-43 (TAR DNA binding protein of 43 kDa; gene name TARDBP) is a 414 amino acid (aa) nuclear RNA/DNA binding phosphoprotein that regulates transcription and splicing.  TDP-43 is aberrantly expressed in most forms of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration.  In these cases it is absent from the nucleus and accumulates, along with a truncated 20-28 kDa form, in the Ubiquitin-containing inclusion bodies.  TDP-43 can also influence CFTR exon 9 skipping in cystic fibrosis.  Human TDP-43 is 96% identical to the mouse ortholog.

1. Buratti E. et al. (2001) EMBO J.  20: 1774.
2. Chen-Plotkin A.S. et al. (2010) Nat. Rev. Neurol.  6: 211.
3. Johnson B.S. et al. (2009) J. Biol. Chem.  284: 20329.
4. Strong M.J. et al. (2007) Mol. Cell Neurosci.  35: 320.

 

Publications for TDP-43/TARDBP (AP-190)(3)

Publications using AP-190

• T Liu, JA Woo, MZ Bukhari, X Wang, Y Yan, SC Buosi, A Ermekbaeva, A Sista, P Kotsiviras, P LePochat, A Chacko, X Zhao, DE Kang Modulation of synaptic plasticity, motor unit physiology, and TDP-43 pathology by CHCHD10 Acta neuropathologica communications, 2022-07-04;10(1):95. 2022-07-04 [PMID: 35787294] (Bioassay, Human)
• H Quek, C Cuní-López, R Stewart, T Colletti, A Notaro, TH Nguyen, Y Sun, CC Guo, MK Lupton, TL Roberts, YC Lim, LE Oikari, V La Bella, AR White ALS monocyte-derived microglia-like cells reveal cytoplasmic TDP-43 accumulation, DNA damage, and cell-specific impairment of phagocytosis associated with disease progression Journal of Neuroinflammation, 2022-02-28;19(1):58. 2022-02-28 [PMID: 35227277] (Bioassay, Human)
• N Ouassil, RL Pinals, JT Del Bonis-, JW Wang, MP Landry Supervised learning model predicts protein adsorption to carbon nanotubes Science Advances, 2022-01-07;8(1):eabm0898. 2022-01-07 [PMID: 34995109] (Bioassay, Human)

FAQs for TDP-43/TARDBP (AP-190). (Showing 1 - 1 of 1 FAQs).

1. Does the Recombinant Human TDP-43/TARDBP Protein (Catalog # AP-190-100) contain a tag?
   • AP-190 is the full-length protein and it does not contain any tags. The predicted molecular mass for this protein is 45 kDa, which matches the sequence stated in the datasheet linked here: https://www.ncbi.nlm.nih.gov/protein/NP_031401.1

Bioinformatics

• Uniprot:
  • NP_031401.1()